Metagenomi, Inc. (MGX)
(Delayed Data from NSDQ)
$2.05 USD
-0.09 (-4.21%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.06 +0.01 (0.49%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MGX 2.05 -0.09(-4.21%)
Will MGX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MGX
Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates
MGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
BeOne Medicines Ltd. - Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains?
Metagenomi (MGX) Reports Q1 Loss, Misses Revenue Estimates
Other News for MGX
MGX forms MACD Bullish Centerline Cross on September 20
Crossed Above 50 Day Moving Average appears for MGX after 13.83% move
MGX Crossed Above 20 Day Moving Average on September 17
20 Day Moving Average Resistance appears for MGX after 0.55% move
MGX Fell Below 20 Day Moving Average on September 15